Eli Lilly makes modest bet on 'all-in-human' discovery outfit for ALS drugs, deepening bid in precision neurology

Lilly will pay $25 million upfront and up to $694 million in biobucks for licensing rights to four potential programs from Verge Genomics, a San Francisco-based discovery outfit boasting an “all-in-human” discovery and development platform using AI to crunch through data from the biotech’s proprietary brain tissue database, the partners said.